NeuroSense Therapeutics CEO Alon Ben-Noon Buys 250,000 Shares
CEO Alon Ben-Noon purchased 250,000 shares of NeuroSense Therapeutics at $0.80 each.
Key Points
- Alon Ben-Noon, CEO of NeuroSense Therapeutics, bought 250,000 shares on June 16, 2026, at an average price of $0.80 each, totaling $200,000.
- Shares of NasdaqCM:NRSN traded near $0.70 with a 52-week range of $0.63 to $2.52 and a market cap of about $25.5 million.
- Peers like UBS Group AG increased holdings, while Yorkville Advisors Global reduced its stake in NeuroSense.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Alon Ben-Noon, the Chief Executive Officer of NeuroSense Therapeutics Ltd. (NasdaqCM:NRSN), made a significant insider purchase on June 16, 2026. He acquired 250,000 shares at a price of $0.80 each, amounting to a total investment of $200,000. This transaction was not part of a pre-arranged trading plan.
Insider Buying and Selling at NeuroSense Therapeutics Ltd.
On the same day, Or Eisenberg, the Chief Financial Officer, also bought 250,000 shares at the same price. Earlier in the year, Niva Russek-Blum, the Chief Technology Officer, and Hagit Binder, the General Manager, each purchased 200,000 shares on March 26, 2026.
Other Institutional Activity in NeuroSense Therapeutics
Yorkville Advisors Global, LP reduced its holdings by 22,000 shares, ending with 78,000 shares valued at about $58,890. Independent Advisor Alliance added 50,000 shares, bringing its total to 50,000 shares worth approximately $37,750. UBS Group AG increased its stake by 18,225 shares, now holding 49,096 shares valued at roughly $37,067.
NeuroSense Therapeutics Ltd. Stock Up 67.7%
Shares of NeuroSense Therapeutics traded around $0.70. The company has a market cap of approximately $25.5 million. It has a forward P/E ratio that isn't meaningful due to its lack of profitability and a beta of 1.541. The stock's 52-week range is between $0.63 and $2.52, with a 50-day moving average of $0.78 and a 200-day moving average of $0.95.
Analysts Set New Price Targets
On April 8, 2026, D. Boral Capital maintained a 'buy' rating with a price target of $14. Roth Capital initiated coverage with a 'buy' rating and a $3 target on March 10, 2026. The consensus among analysts is a 'strong buy' with an average target price of $6.50 based on three opinions.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd. is a biotechnology company based in Herzliya, Israel, focusing on treatments for neurodegenerative diseases. Their lead product, PrimeC, is in advanced clinical trials for amyotrophic lateral sclerosis. The company also has preclinical projects targeting Parkinson's and Alzheimer's diseases. Founded in 2017, it operates with a small team of 17 employees under CEO Alon Ben-Noon.
Bottom Line
NeuroSense Therapeutics has seen insider buying activity, with CEO Alon Ben-Noon making a notable purchase. Investors often watch insider transactions for potential signals about a company's future. However, it's important to remember that these filings are retrospective and may not reflect current positions.
Get NeuroSense Therapeutics Ltd. alerts
New 13F filings, insider trades, and analyst moves on $NRSN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.